Skip to main content
. 2019 Jun 20;39:36. doi: 10.1186/s40880-019-0383-7

Table 3.

EGFR status subgroup analysis of the ALTER0303 trial

EGFR status Median OS (months) HR (95% CI) P value
Placebo arm Anlotinib arm
Wild-type 6.47 8.87 0.73 (0.55–0.97) 0.022
Sensitive mutationsa 6.27 10.70 0.59 (0.38–0.94) 0.023

EGFR, epidermal growth factor receptor; OS, overall survival; HR, hazard ratio

aSensitive mutations include exon 19 deletion and exon 21 Leu858Arg